Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 3 clinical ...

UCLA’s cancer research has been deeply impactful, with millions of people receiving drugs and therapies developed in Bruin ...

Live webcasts and replays of the Cantor and H.C. Wainwright fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

The trial, named AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB, ...

Experts said the approval of the new treatment combination would bring a ‘fundamental shift’ in care for patients with late-stage disease.

First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma ...

National registry study finds overall survival improved across the board after the introduction of immune checkpoint ...

Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.

Cancer’s future may lie in combination therapy—pairing treatments to outsmart tumors, boost survival, and bring new hope ...

Crescent Biopharma is an early-stage biotech with a promising PD-1/VEGF bispecific antibody. Read why I rate CBIO stock as a ...